Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 aggregate principal amount of its 7.25% Senior Notes due December 30, 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 110,000,000 aggregate principal amount of its 7.256.47% Senior Notes due December September 30, 2029 2030 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 U.S.$200,000,000 aggregate principal amount of its 7.254.53% Senior Notes due December July 30, 2029 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13)14. The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue issuance and sale of $53,500,000 144,812,500 aggregate principal amount of its 7.255.22% Senior Secured Notes due December March 30, 2029 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section Article 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 25,000,000 aggregate principal amount of its 7.258.5% Senior Notes due December 30, 2029 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 25,000,000 aggregate principal amount of its 7.253.86% Senior Notes due December 3022, 2029 2021 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 aggregate 25,000,000 principal amount of its 7.255.29% Senior Notes due December 30March 2, 2029 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by each Purchaser and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 150,000,000 aggregate principal amount of its 7.254.53% Senior Notes due December 30April 19, 2029 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1Schedule 1.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 60,000,000 aggregate principal amount of its 7.254.42% Senior Guaranteed Notes due December 30July 28, 2029 2028 (the “Notes”, ,” such term to include any such notes issued in substitution therefor therefore pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 350,000,000 aggregate principal amount of its 7.253.44% Senior Notes due December 3029, 2029 2030 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 150,000,000 aggregate principal amount of its 7.255.71% Senior Notes due December 3018, 2029 2012 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 75,000,000 aggregate principal amount of its 7.256.66% Senior Notes Guaranteed Notes, due December 30July 31, 2029 2015 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale delivery of $53,500,000 250,000,000 aggregate principal amount of its 7.257% Convertible Senior Notes due December 30, 2029 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 139.2(b) or Section 12). The Notes shall be substantially in the form set out in Exhibit 1, subject to the changes contemplated thereunder for Exchange Notes. Certain capitalized and other terms used in this Note Purchase Agreement (this “Agreement”) are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.B.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 28,000,000 aggregate principal amount of its 7.254.38% Senior Notes due December 30April 1, 2029 2042 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 its 4.75% Senior Unsecured Notes due February 22, 2027 in an aggregate principal amount of its 7.25% Senior Notes due December 30$100,000,000 (as amended, 2029 (the “Notes”, such term restated or otherwise modified from time to include time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement1 hereto.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 £57,000,000 aggregate principal amount of its 7.257.78% Series I Senior Guaranteed Notes due December 30July 31, 2029 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes issued on Closing shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale issuance of $53,500,000 300,000,000 aggregate principal amount of its 7.255.5% Senior Notes due December 30March —, 2029 2015 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1312). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule BA; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 100,000,000 aggregate principal amount of its 7.255.12% Senior Notes due December 3016, 2029 2041 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 350,000,000 aggregate principal amount of its 7.254.27% Senior Notes due December 30January 31, 2029 2031 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Schedule 1‑A. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 350,000,000 aggregate principal amount of its 7.252.32% Senior Notes due December 30October 26, 2029 2030 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 25,000,000 aggregate principal amount of its 7.256.92% Senior Notes due December September 30, 2029 2004 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. .c.Section 2.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 20,000,000 aggregate principal amount of its 7.254.54% Senior Notes due December 30January 31, 2029 2049 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 250,000,000 aggregate principal amount of its 7.254.19% Senior Notes due December 3015, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 200,000,000 aggregate principal amount of its 7.254.87% Senior Secured Notes due December 30February 8, 2029 2021 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 11.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 75,000,000 aggregate principal amount of its 7.256.89% Senior Guaranteed Notes due December 30May 25, 2029 2014 (the “"Notes”, ," such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (i) $53,500,000 140,000,000 aggregate principal amount of its 7.256.63% Senior Notes due December 30May 13, 2029 2019 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 75,000,000 aggregate principal amount of its 7.256.89% Senior Guaranteed Notes due December 30May 25, 2029 2014 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.255.67% Senior Notes due December 30February 27, 2029 2054 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 25,000,000 aggregate principal amount of its 7.254.25% Senior Notes due December 306, 2029 2028 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 100,000,000 aggregate principal amount of its 7.25% Senior Unsecured Notes due December 30, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 70,000,000 aggregate principal amount of its 7.25% Senior Unsecured Notes due December July 30, 2029 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 400,000,000 aggregate principal amount of its 7.255.60% Senior Unsecured Notes due December 30November 29, 2029 2016 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out forth in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references B. References to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 80,000,000 aggregate principal amount of its 7.253.55% Guaranteed Senior Notes due December 3015, 2029 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 100,000,000 aggregate principal amount of its 7.254.22% Senior Secured Notes due December 30August 8, 2029 2022 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.255.59% Senior Notes due December 30September 11, 2029 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 125,000,000 aggregate principal amount of its 7.254.50% Senior Unsecured Notes due December 30February 11, 2029 2026 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 67,000,000 aggregate principal amount of its 7.259.78% Series G Senior Notes due December 301, 2029 2018 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 225,000,000 aggregate principal amount of its 7.25% Senior Notes due December 30May 19, 2029 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 50,000,000 aggregate principal amount of its 7.254.33% Senior Notes due December 30May 15, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 U.S.$150,000,000 aggregate principal amount of its 7.253.67% Senior Unsecured Guaranteed Notes due December 30August 24, 2029 2018 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 250,000,000 aggregate principal amount of its 7.254.12% Senior Notes Notes, Series E, due December 30March 5, 2029 2022 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.254.49% Senior Notes Notes, Series E, due December 30August 16, 2029 2052 (the “Notes”), such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. SECTION 2.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 400,000,000 aggregate principal amount of its 7.255.50% Series C Senior Notes due December May 30, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1Schedule 1.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern. Section 1.2.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 50,000,000 aggregate principal amount of its 7.252.94% Senior Notes due December 30November 15, 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 350,000,000 aggregate principal amount of its 7.253.29% Senior Notes due December 30March 17, 2029 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.255.50% Senior Notes due December 30February 24, 2029 2053 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $53,500,000 40,000,000 aggregate principal amount of its 7.253.76% Senior Notes Notes, due December 30January 15, 2029 2052 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 425,000,000 aggregate principal amount of its 7.253.79% Guaranteed Senior Secured Notes due December 30June 26, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references B and, for purposes of this Agreement, the rules of construction set forth in Section 24.4 shall govern. References to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale issuance of $53,500,000 300,000,000 aggregate principal amount of its 7.255.5% Senior Notes due December 30March 31, 2029 2015 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1312). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule BA; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 450,000,000 aggregate principal amount of its 7.253.43% Senior Notes due December 30August 31, 2029 2050 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 15,000,000 aggregate principal amount of its 7.253.23% Senior Notes due December 30October 1, 2029 2040 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 its 7.61% guaranteed senior notes due August 11, 2008 in an aggregate principal amount of its 7.25% Senior Notes due December 30, 2029 $60,000,000 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1314 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized , with such changes therefrom, if any, as may be approved by you and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreementthe Company.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 U.S.$55,000,000 aggregate principal amount of its 7.258.06% Senior Unsecured Guaranteed Notes due December 30August 9, 2029 2014 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 105,000,000 aggregate principal amount of its 7.254.77% Senior Notes due December 30July 16, 2029 2024 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 125,000,000 aggregate principal amount of its 7.253.25% Senior Notes due December 30February 25, 2029 2028 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 100,000,000 aggregate principal amount of its 7.253.97% Senior Notes due December June 30, 2029 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 30,000,000 aggregate principal amount of its 7.253.24% Senior Notes due December September 30, 2029 2050 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 50,000,000 aggregate principal amount of its 7.256.12% Senior Notes due December 30April 28, 2029 2016 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section SECTION 13). The Notes shall be substantially in the form set out in Exhibit EXHIBIT 1. Certain capitalized and other terms used in this Agreement are defined in Schedule SCHEDULE B; and references to a “Schedule” "SCHEDULE" or an “Exhibit” "EXHIBIT" are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of $53,500,000 350,000,000 aggregate principal amount of its 7.255.69% Senior Secured Notes due December 30July 15, 2029 2027 (the “Notes”as amended, such term restated or otherwise modified from time to include time pursuant to Section 18 and including any such notes Notes issued in substitution therefor pursuant to Section 1314, the "Notes"). The Notes shall be substantially in the form set out in Exhibit 1Schedule 1.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 24.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 aggregate principal amount of its 7.25500,000,000 3.90% Senior Notes due December 30April 7, 2029 2032 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 11,000,000 aggregate principal amount of its 7.258.01% Senior Notes due December 30August 11, 2029 2015 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 95,000,000 aggregate principal amount of its 7.253.98% Senior Notes Secured Notes, Series A, due December 30September 29, 2029 2019 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references A. References to a “Schedule” or an “Exhibit” are, are references to a Schedule attached to this Agreement unless otherwise specified, . References to a Schedule or an Exhibit attached “Section” are references to a Section of this AgreementAgreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 30,000,000 aggregate principal amount of its 7.253.11% Senior Notes Notes, due December 30October 1, 2029 2027 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 U.S.$200,000,000 aggregate principal amount of its 7.256.31% Senior Unsecured Guaranteed Notes due December 30July 13, 2029 2011 (the “"Notes”, ," such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 90,000,000 aggregate principal amount of its 7.255.77% Senior Notes due December 30March 27, 2029 2013 (the “"Notes”", such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement or the Other Agreements (as hereinafter defined)). The Notes shall be substantially in the form set out in Exhibit 11.1, with such changes therefrom, if any, as may be approved by you and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “"Schedule” " or an “"Exhibit” " are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 30,000,000 aggregate principal amount of its 7.254.74% Senior Notes due December 30February 26, 2029 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 150,000,000 aggregate principal amount of its 7.254.84% Senior Notes due December 30April 27, 2029 2020 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.254.53% Senior Notes Notes, Series 2012F, due December 30September 1, 2029 2032, (the “Notes.”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 115,000,000 aggregate principal amount of its 7.253.82% Senior Notes Notes, Series A, due December 30February 19, 2029 2030 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 11.1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 25,000,000 aggregate principal amount of its 7.253.31% Senior Notes due December 3015, 2029 2022 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 30,000,000 aggregate principal amount of its 7.25% Floating Rate Senior Notes due December 30, 2029 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. A. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 €175,000,000 aggregate principal amount of its 7.254.50% Senior Notes due December 30March 9, 2029 2014 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 40,000,000 aggregate principal amount of its 7.255.375% Senior Notes due December 30October 20, 2029 2025 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 75,000,000 aggregate principal amount of its 7.254.91% Senior Notes due December 30September 29, 2029 2015 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 175,000,000 aggregate principal amount of its 7.255.20% Senior Notes Notes, due December 30June 15, 2029 2018 (the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of $53,500,000 30,000,000 aggregate principal amount of its 7.256.00% Senior Notes due December 30August 7, 2029 2023 (the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit Schedule 1. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.